A confirmatory, prospective, open-label, multi-centre phase 3 study to evaluate diagnostic performance of 89 Zirconium-labelled girentuximab (89Zr-TLX250) to non-invasively detect clear cell renal cell carcinoma (ccRCC) by positron emission tomography/CT (PET/CT) imaging in patients with indeterminate renal masses [Zr-TLX250-003] [ZIRCON].

  • Frydenberg, Mark (Primary Chief Investigator (PCI))
  • Baker, Emma (Project Manager)
  • Thompson, Katherine (Project Manager)

Project: Research

Project Details

Effective start/end date25/06/2031/12/21


  • Urologic Oncology
  • Renal cell carcinoma
  • Clinical trial